[1] 李雪梅,蔡华聪,王迁,等. 系统性红斑狼疮合并淋巴瘤临床特征[J]. 中华临床免疫和变态反应杂志,2012,6(3):204-209. DOI:10.3969/j.issn.1673-8705.2012.03.009.
[2] 张明智,闫相涛. 自身免疫病相关性淋巴瘤的研究现状[J]. 白血病•淋巴瘤,2010,19(2):68-70,81. DOI:10.3760/cma.j.issn.1009-9921.2010.02.002.
[3] Zou HY, Gu X, Yu WZ, et al. Detection of serum antinuclear antibodies in lymphoma patients [J]. Genet Mol Res, 2015, 14(4):16546-16552. DOI: 10.4238/2015.
[4] 周云杉,应志涛,李茹,等. 淋巴瘤患者血清中抗磷脂自身抗体的临床及免疫学意义[J]. 中华医学杂志,2011,91(37):2607-2610. DOI:10.3760/cma.j.issn.0376-2491.2011. 37.007.
[5] Levine AM, Thornton P, Forman SJ, et al. Positive Coombs test in Hodgkin's disease: significance and implications [J]. Blood, 1980, 55(4): 607-611.
[6] de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development [J]. Nat Rev Cancer, 2006, 6(1):24-37. DOI: 10.1038/nrc1782. PMID: 16397525.
[7] Yao X, Huang J, Zhong H, Shen N, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers [J]. Pharmacol Ther, 2014, 141(2):125-139. DOI: 10.1016/j.pharmthera.2013.09.004.
[8] Maier-Moore JS, Horton CG, Mathews SA, et al. Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice [J]. Arthritis Rheumatol, 2014, 66(9): 2521-2531. DOI: 10.1002/art.38716.
[9] Pillemer SR. Lymphoma and other malignancies in primary Sjögren's syndrome [J]. Ann Rheum Dis, 2006, 65(6): 704-706. DOI: 10.1136/ard.2005.044362.
[10] Hanlon P, Avenell A, Aucott L, et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus [J]. Arthritis Res Ther, 2014, 16(1): R3. DOI: 10.1186/ar4429.
[11] Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics [J]. Cancer Epidemiol Biomarkers Prev, 2006,15(11):2069-77. DOI: 10.1158/1055-9965.EPI-06-0300.
[12] Veeranki S, Choubey D. Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins [J]. Immunol Lett, 2010, 133(1): 1-5. DOI: 10.1016/j.imlet.2010.06.008.
[13] Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study [J]. Ann Rheum Dis, 2008, 67(1):74-79. DOI: 10.1136/ard.2006. 069039.
[14] 郭金燕,任志刚,宣依依,等. 系统性红斑狼疮合并肿瘤患者的临床特点及危险因素分析[J]. 中华内科杂志,2020,59(3):218-221. DOI:10.3760/cma.j.issn.0578-1426.2020. 03.009.
[15] Kang KY, Kim HO, Yoon HS, et al. Incidence of cancer among female patients with systemic lupus erythematosus in Korea [J]. Clin Rheumatol, 2010, 29(4): 381-388. DOI: 10.1007/s10067-009-1332-7.
[16] Sliesoraitis S, Khan R, Rothman J. Methotrexate-induced Hodgkin disease in a patient with systemic lupus erythematosus [J]. J Am Osteopath Assoc, 2009, 109(6):325-328.
[17] Verbaanderd C, Maes H, Schaaf MB, et al. Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents [J]. Ecancermedicalscience, 2017, 11:781. DOI: 10.3332/ecancer.2017.781.
[18] Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus [J]. Ann Rheum Dis, 2007, 66(6): 815-817. DOI: 10.1136/ard.2006.067777.
|